Anti-HER2 antibody DOTA-pertuzumab conjugation and labelling studies with Ac-225
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F22%3A00361724" target="_blank" >RIV/68407700:21340/22:00361724 - isvavai.cz</a>
Result on the web
<a href="https://link.springer.com/article/10.1007/s00259-022-05924-4" target="_blank" >https://link.springer.com/article/10.1007/s00259-022-05924-4</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Anti-HER2 antibody DOTA-pertuzumab conjugation and labelling studies with Ac-225
Original language description
The overexpression of human epidermal growth factor receptor type 2 (HER2) is observed in various tumours. It serves as a prognostic and predictive biomarker. Targeting of HER2 receptors by monoclonal antibodies such as trastuzumab or pertuzumab is used in immunotherapy of these diseases]. The similar targeting concept can and has been applied in radioimmunotherapy. In recent years the most focus is placed on use of alpha-emitting radionuclides which makes radioimmunotherapy a part of targeted alpha-particle therapy. The most studied radionuclides are therefore At-211, Pb-212 or Ac-225. The use of Ac-225 can be especially benefcial thanks to the enormous energy released per one decay. Even though, this radionuclide has already been studied in labelling of various monoclonal antibodies and nanobodies, labelling of pertuzumab monoclonal antibody has been neglected. In this study the conjugation of pertuzumab with DOTA-NHS bifunctional chelator and radiolabelling of prepared conjugates by Ac-225 was performed. The concentration of conjugate was confrmed by UV spectrometry and the conjugate was characterized by MALDI-TOF-MS. The radiolabeling was carried out for various conjugate:radionuclide molar ratios and reaction volumes and pH. The kinetics of radiolabelling was tested by TLC.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
10402 - Inorganic and nuclear chemistry
Result continuities
Project
<a href="/en/project/TJ04000129" target="_blank" >TJ04000129: Separation of radionuclides for targeted alpha particle therapy</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů